Zhou Hao, Tada Takuya, Dcosta Belinda M, Landau Nathaniel R
bioRxiv. 2022 Feb 24:2022.02.15.480166. doi: 10.1101/2022.02.15.480166.
Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly successful in decreasing disease severity; however, the recent emergence of the heavily mutated Omicron variant has posed a challenge to this treatment strategy. The Omicron variant BA.1 has been found to evade neutralization by several of the therapeutic monoclonal antibodies authorized for emergency use, while Vir-7831 and a cocktail consisting of monoclonal antibodies AZD8895+AZD1061 retain significant neutralizing activity. A newly emerged variant, Omicron BA.2, containing some of the BA.1 mutations plus an additional 6 mutations and 3 deletions, 3 of which lie in the receptor binding domain, has been found to be spreading with increased transmissibility. We report here, using spike protein-pseudotyped lentiviruses, decreased neutralization of BA.2 by several therapeutic monoclonal antibodies but that the mixture of AZD8895+AZD1061 retained substantial neutralizing activity against BA.2.
单克隆抗体疗法在治疗SARS-CoV-2感染方面已取得巨大成功，能有效降低疾病严重程度；然而，最近出现的高度变异的奥密克戎变种给这一治疗策略带来了挑战。已发现奥密克戎变种BA.1能逃避几种获批紧急使用的治疗性单克隆抗体的中和作用，而Vir-7831以及由单克隆抗体AZD8895+AZD1061组成的鸡尾酒疗法仍保留显著的中和活性。一种新出现的变种奥密克戎BA.2，包含一些BA.1的突变以及另外6个突变和3个缺失，其中3个位于受体结合域，已发现其传播性增强。我们在此报告，利用刺突蛋白假型慢病毒，几种治疗性单克隆抗体对BA.2的中和作用减弱，但AZD8895+AZD1061混合物对BA.2仍保留大量中和活性。
